Testhyperlink123: Difference between revisions
Jump to navigation
Jump to search
Guptareeya53 (talk | contribs) No edit summary |
Guptareeya53 (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
'''glycan_dictionary_accession''' : GSD000087 <br> | '''glycan_dictionary_accession''' : GSD000087 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00061MO G00061MO] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00061MO G00061MO] <br> | ||
'''term_in_sentence''' : Results of TLC immunostaining of neutral glycolipids from the cDNA-transfected cells also supported the identity of the newly synthesized component as globoside. [PMID:[https://pubmed.ncbi.nlm.nih.gov/ | '''term_in_sentence''' : Results of TLC immunostaining of neutral glycolipids from the cDNA-transfected cells also supported the identity of the newly synthesized component as globoside. [PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10993897 10993897] [https://pubmed.ncbi.nlm.nih.gov/10993897 10993897]]] <br> | ||
'''publication''' : | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/10993897 10993897] <br> | ||
'''definition''' : <br> | '''definition''' : <br> | ||
'''term_xref''' : GlycoMotif:GGM.000070|GTC:G00061MO <br> | '''term_xref''' : GlycoMotif:GGM.000070|GTC:G00061MO <br> | ||
| Line 20: | Line 20: | ||
'''glycan_dictionary_accession''' : GSD000088 <br> | '''glycan_dictionary_accession''' : GSD000088 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00061MO G00061MO] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00061MO G00061MO] <br> | ||
'''term_in_sentence''' : Here we report that PUGNAc treatment provokes globotetraosylceramide (Gb4Cer) accumulation in human umbilical vein endothelial cells (HUVEC).[PMID:[https://pubmed.ncbi.nlm.nih.gov/ | '''term_in_sentence''' : Here we report that PUGNAc treatment provokes globotetraosylceramide (Gb4Cer) accumulation in human umbilical vein endothelial cells (HUVEC).[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/28392398 28392398] [https://pubmed.ncbi.nlm.nih.gov/28392398 28392398]]] <br> | ||
'''publication''' : | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28392398 28392398]|[https://pubmed.ncbi.nlm.nih.gov/25787850 25787850]|[https://pubmed.ncbi.nlm.nih.gov/23471986 23471986]|[https://pubmed.ncbi.nlm.nih.gov/2559078 2559078]|[https://pubmed.ncbi.nlm.nih.gov/32455599 32455599]|[https://pubmed.ncbi.nlm.nih.gov/2663859 2663859]|[https://pubmed.ncbi.nlm.nih.gov/32796033 32796033]|[https://pubmed.ncbi.nlm.nih.gov/3517161 3517161]|[https://pubmed.ncbi.nlm.nih.gov/20082214 20082214]|[https://pubmed.ncbi.nlm.nih.gov/30853699 30853699]|[https://pubmed.ncbi.nlm.nih.gov/15279935 15279935]|[https://pubmed.ncbi.nlm.nih.gov/26104834 26104834]|[https://pubmed.ncbi.nlm.nih.gov/20732996 20732996]|[https://pubmed.ncbi.nlm.nih.gov/30224239 30224239]|[https://pubmed.ncbi.nlm.nih.gov/31142708 31142708]|[https://pubmed.ncbi.nlm.nih.gov/30338271 30338271]|[https://pubmed.ncbi.nlm.nih.gov/25033755 25033755]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/30413389 30413389] [https://pubmed.ncbi.nlm.nih.gov/30413389 30413389]]|[https://pubmed.ncbi.nlm.nih.gov/7104376 7104376]|[https://pubmed.ncbi.nlm.nih.gov/29866658 29866658]|[https://pubmed.ncbi.nlm.nih.gov/24983355 24983355]|[https://pubmed.ncbi.nlm.nih.gov/6794884 6794884]|[https://pubmed.ncbi.nlm.nih.gov/31361021 31361021]|[https://pubmed.ncbi.nlm.nih.gov/21740983 21740983]|[https://pubmed.ncbi.nlm.nih.gov/33168837 33168837]|[https://pubmed.ncbi.nlm.nih.gov/31752441 31752441]|[https://pubmed.ncbi.nlm.nih.gov/28123520 28123520]|[https://pubmed.ncbi.nlm.nih.gov/29068380 29068380]|[https://pubmed.ncbi.nlm.nih.gov/24841197 24841197]|[https://pubmed.ncbi.nlm.nih.gov/27932383 27932383]|[https://pubmed.ncbi.nlm.nih.gov/28535204 28535204]|[https://pubmed.ncbi.nlm.nih.gov/31691795 31691795]|[https://pubmed.ncbi.nlm.nih.gov/27916888 27916888]|[https://pubmed.ncbi.nlm.nih.gov/27558838 27558838]|[https://pubmed.ncbi.nlm.nih.gov/10227680 10227680]|[https://pubmed.ncbi.nlm.nih.gov/26464281 26464281]|[https://pubmed.ncbi.nlm.nih.gov/22348006 22348006]|[https://pubmed.ncbi.nlm.nih.gov/22279060 22279060]|[https://pubmed.ncbi.nlm.nih.gov/25156739 25156739]|[https://pubmed.ncbi.nlm.nih.gov/32314902 32314902]|[https://pubmed.ncbi.nlm.nih.gov/22718629 22718629]|[https://pubmed.ncbi.nlm.nih.gov/23701631 23701631]|[https://pubmed.ncbi.nlm.nih.gov/23906628 23906628]|[https://pubmed.ncbi.nlm.nih.gov/8613382 8613382]|[https://pubmed.ncbi.nlm.nih.gov/23555772 23555772]|[https://pubmed.ncbi.nlm.nih.gov/20059899 20059899]|[https://pubmed.ncbi.nlm.nih.gov/7868240 7868240] <br> | ||
'''definition''' : An amino tetrasaccharide consisting of 2-acetamido-2-deoxy-β-D-galactopyranosyl, α-D-galactopyranosyl, β-D-galactopyranosyl, and β-D-glucopyranose units joined together in sequence by (1→3), (1→4), and (1→4) glycosidic linkages, respectively.[CHEBI:145578] <br> | '''definition''' : An amino tetrasaccharide consisting of 2-acetamido-2-deoxy-β-D-galactopyranosyl, α-D-galactopyranosyl, β-D-galactopyranosyl, and β-D-glucopyranose units joined together in sequence by (1→3), (1→4), and (1→4) glycosidic linkages, respectively.[CHEBI:145578] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000070|GlycoEpitope:EP0073|CID:[https://pubmed.ncbi.nlm.nih.gov/5288889 5288889]|CHEBI:145578|SugarBind_Ligand:18|MeSH:C024032<br> | '''term_xref''' : GlycoMotif:GGM.000070|GlycoEpitope:EP0073|CID:[https://pubmed.ncbi.nlm.nih.gov/5288889 5288889]|CHEBI:145578|SugarBind_Ligand:18|MeSH:C024032<br> | ||
| Line 36: | Line 36: | ||
'''glycan_dictionary_accession''' : GSD000089 <br> | '''glycan_dictionary_accession''' : GSD000089 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00059MO G00059MO] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00059MO G00059MO] <br> | ||
'''term_in_sentence''' : Defects in the gene encoding α-galactosidase A lead to accumulation of globotriaosylceramide (GL3) in various cell types.[PMID:[https://pubmed.ncbi.nlm.nih.gov/ | '''term_in_sentence''' : Defects in the gene encoding α-galactosidase A lead to accumulation of globotriaosylceramide (GL3) in various cell types.[PMID:[https://pubmed.ncbi.nlm.nih.gov/32127409 32127409]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/ | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/32127409 32127409]|[https://pubmed.ncbi.nlm.nih.gov/28674962 28674962]|[https://pubmed.ncbi.nlm.nih.gov/30875019 30875019]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/30413389 30413389] [https://pubmed.ncbi.nlm.nih.gov/30413389 30413389]]|[https://pubmed.ncbi.nlm.nih.gov/31778662 31778662]|[https://pubmed.ncbi.nlm.nih.gov/31101366 31101366]|[https://pubmed.ncbi.nlm.nih.gov/24335674 24335674]|[https://pubmed.ncbi.nlm.nih.gov/31241709 31241709]|[https://pubmed.ncbi.nlm.nih.gov/24158513 24158513]|[https://pubmed.ncbi.nlm.nih.gov/28947349 28947349]|[https://pubmed.ncbi.nlm.nih.gov/31566927 31566927]|[https://pubmed.ncbi.nlm.nih.gov/28672034 28672034]|[https://pubmed.ncbi.nlm.nih.gov/31939530 31939530]|[https://pubmed.ncbi.nlm.nih.gov/29530250 29530250]|[https://pubmed.ncbi.nlm.nih.gov/27851774 27851774]|[https://pubmed.ncbi.nlm.nih.gov/26426881 26426881]|[https://pubmed.ncbi.nlm.nih.gov/25031264 25031264]|[https://pubmed.ncbi.nlm.nih.gov/29982630 29982630]|[https://pubmed.ncbi.nlm.nih.gov/24496231 24496231]|[https://pubmed.ncbi.nlm.nih.gov/29983334 29983334]|[https://pubmed.ncbi.nlm.nih.gov/28756410 28756410]|[https://pubmed.ncbi.nlm.nih.gov/27190352 27190352]|[https://pubmed.ncbi.nlm.nih.gov/29274327 29274327]|[https://pubmed.ncbi.nlm.nih.gov/29099167 29099167]|[https://pubmed.ncbi.nlm.nih.gov/28402705 28402705]|[https://pubmed.ncbi.nlm.nih.gov/23680766 23680766]|[https://pubmed.ncbi.nlm.nih.gov/28625968 28625968]|[https://pubmed.ncbi.nlm.nih.gov/26960552 26960552]|[https://pubmed.ncbi.nlm.nih.gov/26797827 26797827]|[https://pubmed.ncbi.nlm.nih.gov/22742555 22742555]|[https://pubmed.ncbi.nlm.nih.gov/27756537 27756537]|[https://pubmed.ncbi.nlm.nih.gov/31630715 31630715]|[https://pubmed.ncbi.nlm.nih.gov/3827883 3827883]|[https://pubmed.ncbi.nlm.nih.gov/28384397 28384397]|[https://pubmed.ncbi.nlm.nih.gov/29523338 29523338]|[https://pubmed.ncbi.nlm.nih.gov/31010832 31010832]|[https://pubmed.ncbi.nlm.nih.gov/27195818 27195818]|[https://pubmed.ncbi.nlm.nih.gov/26661087 26661087]|[https://pubmed.ncbi.nlm.nih.gov/23093409 23093409]|[https://pubmed.ncbi.nlm.nih.gov/30879639 30879639]|[https://pubmed.ncbi.nlm.nih.gov/27081853 27081853]|[https://pubmed.ncbi.nlm.nih.gov/17409683 17409683]|[https://pubmed.ncbi.nlm.nih.gov/29921669 29921669]|[https://pubmed.ncbi.nlm.nih.gov/25575293 25575293]|[https://pubmed.ncbi.nlm.nih.gov/26291612 26291612]|[https://pubmed.ncbi.nlm.nih.gov/23146289 23146289]|[https://pubmed.ncbi.nlm.nih.gov/25857295 25857295]|[https://pubmed.ncbi.nlm.nih.gov/26070511 26070511] <br> | ||
'''definition''' : Globotriaosylceramide is a type of globoside(glycosphingolipid) which is formed by alpha linkage of galactose to lactosylceramide. The reaction is catalyzed by enzyme A4GALT.[Wiki:Globotriaosylceramide] <br> | '''definition''' : Globotriaosylceramide is a type of globoside(glycosphingolipid) which is formed by alpha linkage of galactose to lactosylceramide. The reaction is catalyzed by enzyme A4GALT.[Wiki:Globotriaosylceramide] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000068|GTC:G00059MO|GlycoEpitope:EP0071|CID:[https://pubmed.ncbi.nlm.nih.gov/5279515 5279515]|CHEBI:68485|MeSH:C018549|SugarBind_Ligand:27 <br> | '''term_xref''' : GlycoMotif:GGM.000068|GTC:G00059MO|GlycoEpitope:EP0071|CID:[https://pubmed.ncbi.nlm.nih.gov/5279515 5279515]|CHEBI:68485|MeSH:C018549|SugarBind_Ligand:27 <br> | ||
| Line 52: | Line 52: | ||
'''glycan_dictionary_accession''' : GSD000090 <br> | '''glycan_dictionary_accession''' : GSD000090 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G71142DF G71142DF] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G71142DF G71142DF] <br> | ||
'''term_in_sentence''' : Glucosylceramide (GlcCer), the initial GSL synthesized from ceramide by GCS (GlcCer synthase), is required for embryonic survival, but its role in the lung is unknown.[PMID:[https://pubmed.ncbi.nlm.nih.gov/ | '''term_in_sentence''' : Glucosylceramide (GlcCer), the initial GSL synthesized from ceramide by GCS (GlcCer synthase), is required for embryonic survival, but its role in the lung is unknown.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31265321 31265321]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/ | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31265321 31265321]|[https://pubmed.ncbi.nlm.nih.gov/29290548 29290548]|[https://pubmed.ncbi.nlm.nih.gov/29627573 29627573]|[https://pubmed.ncbi.nlm.nih.gov/20919653 20919653]|[https://pubmed.ncbi.nlm.nih.gov/28427052 28427052]|[https://pubmed.ncbi.nlm.nih.gov/30550553 30550553]|[https://pubmed.ncbi.nlm.nih.gov/24415933 24415933]|[https://pubmed.ncbi.nlm.nih.gov/31914593 31914593]|[https://pubmed.ncbi.nlm.nih.gov/31051284 31051284]|[https://pubmed.ncbi.nlm.nih.gov/23073611 23073611]|[https://pubmed.ncbi.nlm.nih.gov/30146946 30146946]|[https://pubmed.ncbi.nlm.nih.gov/31619618 31619618]|[https://pubmed.ncbi.nlm.nih.gov/26840726 26840726]|[https://pubmed.ncbi.nlm.nih.gov/29750412 29750412]|[https://pubmed.ncbi.nlm.nih.gov/8065509 8065509]|[https://pubmed.ncbi.nlm.nih.gov/27412675 27412675]|[https://pubmed.ncbi.nlm.nih.gov/27840079 27840079]|[https://pubmed.ncbi.nlm.nih.gov/30611744 30611744]|[https://pubmed.ncbi.nlm.nih.gov/31353719 31353719]|[https://pubmed.ncbi.nlm.nih.gov/25661072 25661072]|[https://pubmed.ncbi.nlm.nih.gov/28686011 28686011]|[https://pubmed.ncbi.nlm.nih.gov/25803043 25803043]|[https://pubmed.ncbi.nlm.nih.gov/28865794 28865794]|[https://pubmed.ncbi.nlm.nih.gov/28154347 28154347]|[https://pubmed.ncbi.nlm.nih.gov/31466334 31466334]|[https://pubmed.ncbi.nlm.nih.gov/30242129 30242129]|[https://pubmed.ncbi.nlm.nih.gov/12531551 12531551]|[https://pubmed.ncbi.nlm.nih.gov/30639288 30639288]|[https://pubmed.ncbi.nlm.nih.gov/30864417 30864417]|[https://pubmed.ncbi.nlm.nih.gov/27711049 27711049]|[https://pubmed.ncbi.nlm.nih.gov/22764777 22764777]|[https://pubmed.ncbi.nlm.nih.gov/27905603 27905603]|[https://pubmed.ncbi.nlm.nih.gov/29077010 29077010]|[https://pubmed.ncbi.nlm.nih.gov/28744000 28744000]|[https://pubmed.ncbi.nlm.nih.gov/23555901 23555901]|[https://pubmed.ncbi.nlm.nih.gov/24115322 24115322]|[https://pubmed.ncbi.nlm.nih.gov/12803919 12803919]|[https://pubmed.ncbi.nlm.nih.gov/29204666 29204666]|[https://pubmed.ncbi.nlm.nih.gov/23628459 23628459]|[https://pubmed.ncbi.nlm.nih.gov/28851512 28851512]|[https://pubmed.ncbi.nlm.nih.gov/26136173 26136173]|[https://pubmed.ncbi.nlm.nih.gov/23563543 23563543]|[https://pubmed.ncbi.nlm.nih.gov/30110701 30110701]|[https://pubmed.ncbi.nlm.nih.gov/26572681 26572681]|[https://pubmed.ncbi.nlm.nih.gov/2193825 2193825]|[https://pubmed.ncbi.nlm.nih.gov/29926415 29926415]|[https://pubmed.ncbi.nlm.nih.gov/31727994 31727994]|[https://pubmed.ncbi.nlm.nih.gov/27479571 27479571] <br> | ||
'''definition''' : Cerebrosides which contain as their polar head group a glucose moiety bound in glycosidic linkage to the hydroxyl group of ceramides. Their accumulation in tissue, due to a defect in beta-glucosidase, is the cause of Gaucher's disease.[MeSH:D005963] <br> | '''definition''' : Cerebrosides which contain as their polar head group a glucose moiety bound in glycosidic linkage to the hydroxyl group of ceramides. Their accumulation in tissue, due to a defect in beta-glucosidase, is the cause of Gaucher's disease.[MeSH:D005963] <br> | ||
'''term_xref''' : MeSH:D005963|GlycoMotif:GGM.000060|CHEBI:83264|GTC:G71142DF <br> | '''term_xref''' : MeSH:D005963|GlycoMotif:GGM.000060|CHEBI:83264|GTC:G71142DF <br> | ||
'''synonyms''' : GlcCer|Glucocerebroside|Ceramide monohexoside|CMH <br> | '''synonyms''' : GlcCer|Glucocerebroside|Ceramide monohexoside|CMH <br> | ||
'''function''' : The structural characterization of mixed membranes made of cationic lipids and glucosylceramides may be important for developing novel immunotherapeutic tools such as vaccine adjuvants.[PMID:[https://pubmed.ncbi.nlm.nih.gov/ | '''function''' : The structural characterization of mixed membranes made of cationic lipids and glucosylceramides may be important for developing novel immunotherapeutic tools such as vaccine adjuvants.[PMID:[https://pubmed.ncbi.nlm.nih.gov/30611744 30611744]]|Glucosylceramide (GlcCer), the initial GSL synthesized from ceramide by GCS (GlcCer synthase), is required for embryonic survival, but its role in the lung is unknown.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31265321 31265321]] <br> | ||
'''disease_associations''' : Gaucher's Disease|Pharyngitis[SugarBind_Ligand:3]|Tracheobronchitis[SugarBind_Ligand:3]|Pleuropneumonia[SugarBind_Ligand:3]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:3]|Diarrhea[SugarBind_Ligand:3] <br> | '''disease_associations''' : Gaucher's Disease|Pharyngitis[SugarBind_Ligand:3]|Tracheobronchitis[SugarBind_Ligand:3]|Pleuropneumonia[SugarBind_Ligand:3]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:3]|Diarrhea[SugarBind_Ligand:3] <br> | ||
'''wikipedia''' : <br> | '''wikipedia''' : <br> | ||
| Line 68: | Line 68: | ||
'''glycan_dictionary_accession''' : GSD000091 <br> | '''glycan_dictionary_accession''' : GSD000091 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G48558GR G48558GR] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G48558GR G48558GR] <br> | ||
'''term_in_sentence''' : GM1-induced fluidization of the phospholipid membranes and probable physical contact between bulky sugar head group of GM1 and spectrin, may explain the modulatory role of GM1 on aminophospholipid interactions with nonerythroid brain spectrin.[PMID: | '''term_in_sentence''' : GM1-induced fluidization of the phospholipid membranes and probable physical contact between bulky sugar head group of GM1 and spectrin, may explain the modulatory role of GM1 on aminophospholipid interactions with nonerythroid brain spectrin.[PMID: 29920238] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/ | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/18524657 18524657]|[https://pubmed.ncbi.nlm.nih.gov/31761138 31761138]|[https://pubmed.ncbi.nlm.nih.gov/36180805 36180805]|[https://pubmed.ncbi.nlm.nih.gov/29920238 29920238]|[https://pubmed.ncbi.nlm.nih.gov/33859490 33859490]'''|'''[https://pubmed.ncbi.nlm.nih.gov/31937438 31937438]|[https://pubmed.ncbi.nlm.nih.gov/25762012 25762012]|[https://pubmed.ncbi.nlm.nih.gov/25931034 25931034]|[https://pubmed.ncbi.nlm.nih.gov/31776384 31776384]|[https://pubmed.ncbi.nlm.nih.gov/32013258 32013258]|[https://pubmed.ncbi.nlm.nih.gov/30776097 30776097]|[https://pubmed.ncbi.nlm.nih.gov/31048748 31048748]|[https://pubmed.ncbi.nlm.nih.gov/31447771 31447771]|[https://pubmed.ncbi.nlm.nih.gov/30292198 30292198]|[https://pubmed.ncbi.nlm.nih.gov/28796418 28796418]|[https://pubmed.ncbi.nlm.nih.gov/27806275 27806275]|[https://pubmed.ncbi.nlm.nih.gov/21076871 21076871]|[https://pubmed.ncbi.nlm.nih.gov/27552916 27552916]|[https://pubmed.ncbi.nlm.nih.gov/17986147 17986147]|[https://pubmed.ncbi.nlm.nih.gov/26960162 26960162]|[https://pubmed.ncbi.nlm.nih.gov/27815022 27815022]|[https://pubmed.ncbi.nlm.nih.gov/25851126 25851126]|[https://pubmed.ncbi.nlm.nih.gov/32916822 32916822]|[https://pubmed.ncbi.nlm.nih.gov/11462671 11462671]|[https://pubmed.ncbi.nlm.nih.gov/28236574 28236574]|[https://pubmed.ncbi.nlm.nih.gov/15911874 15911874]|[https://pubmed.ncbi.nlm.nih.gov/28577204 28577204]|[https://pubmed.ncbi.nlm.nih.gov/28497346 28497346]|[https://pubmed.ncbi.nlm.nih.gov/1794005 1794005]|[https://pubmed.ncbi.nlm.nih.gov/31934908 31934908]|[https://pubmed.ncbi.nlm.nih.gov/30267299 30267299]|[https://pubmed.ncbi.nlm.nih.gov/16902585 16902585]|[https://pubmed.ncbi.nlm.nih.gov/29439846 29439846]|[https://pubmed.ncbi.nlm.nih.gov/32325905 32325905]|[https://pubmed.ncbi.nlm.nih.gov/29747823 29747823]|[https://pubmed.ncbi.nlm.nih.gov/27576485 27576485]|[https://pubmed.ncbi.nlm.nih.gov/26338710 26338710]|[https://pubmed.ncbi.nlm.nih.gov/27858734 27858734]|[https://pubmed.ncbi.nlm.nih.gov/24501414 24501414]|[https://pubmed.ncbi.nlm.nih.gov/26818965 26818965]|[https://pubmed.ncbi.nlm.nih.gov/26629687 26629687]|[https://pubmed.ncbi.nlm.nih.gov/26958633 26958633]|[https://pubmed.ncbi.nlm.nih.gov/1854596 1854596]|[https://pubmed.ncbi.nlm.nih.gov/32134593 32134593]|[https://pubmed.ncbi.nlm.nih.gov/32198666 32198666]|[https://pubmed.ncbi.nlm.nih.gov/6619101 6619101] <br> | ||
'''definition''' : A branched amino pentasaccharide consisting of the linear sequence β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the inner galactose via an α-(2→3) linkage. The oligosaccharide of ganglioside GM1a.[CHEBI:59208] <br> | '''definition''' : A branched amino pentasaccharide consisting of the linear sequence β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the inner galactose via an α-(2→3) linkage. The oligosaccharide of ganglioside GM1a.[CHEBI:59208] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000098|GTC:G48558GR|CID:196569|CHEBI:59208|GlycoEpitope:EP0050|SugarBind_Ligand:13|KEGG:G00110 <br> | '''term_xref''' : GlycoMotif:GGM.000098|GTC:G48558GR|CID:196569|CHEBI:59208|GlycoEpitope:EP0050|SugarBind_Ligand:13|KEGG:G00110 <br> | ||
'''synonyms''' : GM1 ganglioside|GM1-ganglioside<br> | '''synonyms''' : GM1 ganglioside|GM1-ganglioside<br> | ||
'''function''' : The branched pentasaccharide chain of ganglioside GM1 is a prominent cell surface ligand, for example, for cholera toxin or tumor growth-regulatory homodimeric galectins.[PMID:[https://pubmed.ncbi.nlm.nih.gov/ | '''function''' : The branched pentasaccharide chain of ganglioside GM1 is a prominent cell surface ligand, for example, for cholera toxin or tumor growth-regulatory homodimeric galectins.[PMID:[https://pubmed.ncbi.nlm.nih.gov/16267866/ 16267866]]<br> | ||
'''disease_associations''' : GM1 gangliosidosis (GM1) [PMID: [https://pubmed.ncbi.nlm.nih.gov/ | '''disease_associations''' : GM1 gangliosidosis (GM1) [PMID: [https://pubmed.ncbi.nlm.nih.gov/33859490/ 33859490]]|Gastroenteritis[SugarBind_Ligand:13]|Actinomycosis[SugarBind_Ligand:13]|Lazy leukocyte syndrome[SugarBind_Ligand:13]|Toxoplasmosis[SugarBind_Ligand:13]|Cholera[SugarBind_Ligand:13]|Botulism[SugarBind_Ligand:13] <br> | ||
'''wikipedia''' : https://en.wikipedia.org/wiki/GM1 <br> | '''wikipedia''' : https://en.wikipedia.org/wiki/GM1 <br> | ||
'''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]| [https://www.ncbi.nlm.nih.gov/books/NBK579929/ Chapter 14] <br> | '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453016/ Chapter 11]| [https://www.ncbi.nlm.nih.gov/books/NBK579929/ Chapter 14] <br> | ||
| Line 84: | Line 84: | ||
'''glycan_dictionary_accession''' : GSD000092 <br> | '''glycan_dictionary_accession''' : GSD000092 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G79389NT G79389NT] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G79389NT G79389NT] <br> | ||
'''term_in_sentence''' : GM1 gangliosidosis has both central nervous system and systemic findings; while, GM2 gangliosidosis is restricted primarily to the central nervous system.[PMID: | '''term_in_sentence''' : GM1 gangliosidosis has both central nervous system and systemic findings; while, GM2 gangliosidosis is restricted primarily to the central nervous system.[PMID: 27491214] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/ | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29618308 29618308]|[https://pubmed.ncbi.nlm.nih.gov/27491214 27491214]|[https://pubmed.ncbi.nlm.nih.gov/32867370 32867370]|[https://pubmed.ncbi.nlm.nih.gov/30030044 30030044]|[https://pubmed.ncbi.nlm.nih.gov/27499644 27499644]|[https://pubmed.ncbi.nlm.nih.gov/31097363 31097363]|[https://pubmed.ncbi.nlm.nih.gov/29100724 29100724]|[https://pubmed.ncbi.nlm.nih.gov/27402091 27402091]|[https://pubmed.ncbi.nlm.nih.gov/31852956 31852956]|[https://pubmed.ncbi.nlm.nih.gov/30389374 30389374]|[https://pubmed.ncbi.nlm.nih.gov/30988135 30988135]|[https://pubmed.ncbi.nlm.nih.gov/8786814 8786814]|[https://pubmed.ncbi.nlm.nih.gov/14533808 14533808]|[https://pubmed.ncbi.nlm.nih.gov/23370522 23370522]|[https://pubmed.ncbi.nlm.nih.gov/28192816 28192816]|[https://pubmed.ncbi.nlm.nih.gov/32692591 32692591]|[https://pubmed.ncbi.nlm.nih.gov/29106755 29106755]|[https://pubmed.ncbi.nlm.nih.gov/28833537 28833537]|[https://pubmed.ncbi.nlm.nih.gov/11339652 11339652]|[https://pubmed.ncbi.nlm.nih.gov/9728335 9728335]|[https://pubmed.ncbi.nlm.nih.gov/27270764 27270764]|[https://pubmed.ncbi.nlm.nih.gov/9714704 9714704]|[https://pubmed.ncbi.nlm.nih.gov/26175473 26175473]|[https://pubmed.ncbi.nlm.nih.gov/27018595 27018595]|[https://pubmed.ncbi.nlm.nih.gov/28615102 28615102]|[https://pubmed.ncbi.nlm.nih.gov/28974375 28974375]|[https://pubmed.ncbi.nlm.nih.gov/32951593 32951593]|[https://pubmed.ncbi.nlm.nih.gov/11462672 11462672]|[https://pubmed.ncbi.nlm.nih.gov/28955902 28955902]|[https://pubmed.ncbi.nlm.nih.gov/17192692 17192692]|[https://pubmed.ncbi.nlm.nih.gov/26538065 26538065]|[https://pubmed.ncbi.nlm.nih.gov/25421609 25421609]|[https://pubmed.ncbi.nlm.nih.gov/9572057 9572057]|[https://pubmed.ncbi.nlm.nih.gov/11596983 11596983]|[https://pubmed.ncbi.nlm.nih.gov/15264019 15264019]|[https://pubmed.ncbi.nlm.nih.gov/23236285 23236285]|[https://pubmed.ncbi.nlm.nih.gov/11596984 11596984]|[https://pubmed.ncbi.nlm.nih.gov/31261761 31261761]|[https://pubmed.ncbi.nlm.nih.gov/30113798 30113798]|[https://pubmed.ncbi.nlm.nih.gov/24391178 24391178]|[https://pubmed.ncbi.nlm.nih.gov/24309906 24309906]|[https://pubmed.ncbi.nlm.nih.gov/22224667 22224667]|[https://pubmed.ncbi.nlm.nih.gov/7980537 7980537]|[https://pubmed.ncbi.nlm.nih.gov/18272501 18272501]|[https://pubmed.ncbi.nlm.nih.gov/9006924 9006924]| <br> | ||
'''definition''' : A branched amino tetrasaccharide consisting of the linear sequence β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the galactose via an α-(2→3) linkage. Corresponds to the carbohydrate portion of ganglioside GM2.[CHEBI:59220] <br> | '''definition''' : A branched amino tetrasaccharide consisting of the linear sequence β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the galactose via an α-(2→3) linkage. Corresponds to the carbohydrate portion of ganglioside GM2.[CHEBI:59220] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000095|GTC:G79389NT|CID:[https://pubmed.ncbi.nlm.nih.gov/45266845 45266845]|CHEBI:59220|GlycoEpitope:EP0051|SugarBind_Ligand:39|KEGG:G00109|KEGG:G10351 <br> | '''term_xref''' : GlycoMotif:GGM.000095|GTC:G79389NT|CID:[https://pubmed.ncbi.nlm.nih.gov/45266845 45266845]|CHEBI:59220|GlycoEpitope:EP0051|SugarBind_Ligand:39|KEGG:G00109|KEGG:G10351 <br> | ||
| Line 100: | Line 100: | ||
'''glycan_dictionary_accession''' : GSD000093 <br> | '''glycan_dictionary_accession''' : GSD000093 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G91237TK G91237TK] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G91237TK G91237TK] <br> | ||
'''term_in_sentence''' : We also demonstrated an essential role of GM3 in murine and human auditory systems; a common pathological feature of GM3S deficiency is deafness. [PMID: [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/ | '''term_in_sentence''' : We also demonstrated an essential role of GM3 in murine and human auditory systems; a common pathological feature of GM3S deficiency is deafness. [PMID: 29747813] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29376491 29376491]|[https://pubmed.ncbi.nlm.nih.gov/29747813 29747813]|[https://pubmed.ncbi.nlm.nih.gov/25613425 25613425]|[https://pubmed.ncbi.nlm.nih.gov/30318083 30318083]|[https://pubmed.ncbi.nlm.nih.gov/31526872 31526872]|[https://pubmed.ncbi.nlm.nih.gov/31004109 31004109]|[https://pubmed.ncbi.nlm.nih.gov/28019668 28019668]|[https://pubmed.ncbi.nlm.nih.gov/26434718 26434718]|[https://pubmed.ncbi.nlm.nih.gov/27313500 27313500]|[https://pubmed.ncbi.nlm.nih.gov/27539856 27539856]|[https://pubmed.ncbi.nlm.nih.gov/30111401 30111401]|[https://pubmed.ncbi.nlm.nih.gov/28544772 28544772]|[https://pubmed.ncbi.nlm.nih.gov/29407985 29407985]|[https://pubmed.ncbi.nlm.nih.gov/19364317 19364317]|[https://pubmed.ncbi.nlm.nih.gov/30190430 30190430]|[https://pubmed.ncbi.nlm.nih.gov/31297734 31297734]|[https://pubmed.ncbi.nlm.nih.gov/30091781 30091781]|[https://pubmed.ncbi.nlm.nih.gov/26043887 26043887]|[https://pubmed.ncbi.nlm.nih.gov/32183071 32183071]|[https://pubmed.ncbi.nlm.nih.gov/30665141 30665141]|[https://pubmed.ncbi.nlm.nih.gov/27873002 27873002]|[https://pubmed.ncbi.nlm.nih.gov/25801320 25801320]|[https://pubmed.ncbi.nlm.nih.gov/30209782 30209782]|[https://pubmed.ncbi.nlm.nih.gov/32378734 32378734]|[https://pubmed.ncbi.nlm.nih.gov/23050851 23050851]|[https://pubmed.ncbi.nlm.nih.gov/22768242 22768242]|[https://pubmed.ncbi.nlm.nih.gov/14993837 14993837]|[https://pubmed.ncbi.nlm.nih.gov/24934090 24934090]|[https://pubmed.ncbi.nlm.nih.gov/17638075 17638075]|[https://pubmed.ncbi.nlm.nih.gov/21518140 21518140]|[https://pubmed.ncbi.nlm.nih.gov/26102277 26102277]|[https://pubmed.ncbi.nlm.nih.gov/19759399 19759399]|[https://pubmed.ncbi.nlm.nih.gov/24502144 24502144]|[https://pubmed.ncbi.nlm.nih.gov/25303960 25303960]|[https://pubmed.ncbi.nlm.nih.gov/23564406 23564406]|[https://pubmed.ncbi.nlm.nih.gov/16636105 16636105]|[https://pubmed.ncbi.nlm.nih.gov/16491123 16491123]|[https://pubmed.ncbi.nlm.nih.gov/11259118 11259118]|[https://pubmed.ncbi.nlm.nih.gov/15102521 15102521]|[https://pubmed.ncbi.nlm.nih.gov/12724312 12724312]|[https://pubmed.ncbi.nlm.nih.gov/24985965 24985965]|[https://pubmed.ncbi.nlm.nih.gov/8496625 8496625]|[https://pubmed.ncbi.nlm.nih.gov/25403557 25403557]|[https://pubmed.ncbi.nlm.nih.gov/15690123 15690123]|[https://pubmed.ncbi.nlm.nih.gov/15939439 15939439]|[https://pubmed.ncbi.nlm.nih.gov/25893133 25893133]|[https://pubmed.ncbi.nlm.nih.gov/23591593 23591593]|[https://pubmed.ncbi.nlm.nih.gov/20634908 20634908]|[https://pubmed.ncbi.nlm.nih.gov/2004380 2004380]|[https://pubmed.ncbi.nlm.nih.gov/739008 739008]| <br> | |||
'''definition''' : Ganglioside GM3 (d18:1/16:0) is a glycosphingolipid (ceramide and oligosaccharide)or oligoglycosylceramide with one or more sialic acids (i.e. n-acetylneuraminic acid) linked on the sugar chain. It is a component the cell plasma membrane which modulates cell signal transduction events. Gangliosides have been found to be highly important in immunology. Ganglioside GM3 carries a net-negative charge at pH 7.0 and is acidic. Gangliosides can amount to 6% of the weight of lipids from brain, but they are found at low levels in all animal tissuesGangliosides are glycosphingolipids. There are four types of glycosphingolipids, the cerebrosides, sulfatides, globosides and gangliosides. Gangliosides are very similar to globosides except that they also contain N-acetyl neuraminic acid (NANA) in varying amounts. The specific names for the gangliosides provide information about their structure. The letter G refers to ganglioside, and the subscripts M, D, T and Q indicate that the molecule contains mono-, di-, tri and quatra-sialic acid. The numbered subscripts 1, 2 and 3 refer to the carbohydrate sequence that is attached to the ceramide. In particular, 1 stands for GalGalNAcGalGlc-ceramide, 2 stands for GalNAcGalGlc-ceramide and 3 stands for GalGlc-ceramide. Deficiencies in lysosomal enzymes that degrade the carbohydrate portions of various gangliosides are responsible for a number of lysosomal storage diseases such as Tay-Sachs disease, Sandhoff disease, and GM1 gangliosidosis. The carbohydrate portion of the ganglioside GM1 is the site of attachment of cholera toxin, the protein secreted by Vibrio cholerae.[HMDB0004844] <br> | '''definition''' : Ganglioside GM3 (d18:1/16:0) is a glycosphingolipid (ceramide and oligosaccharide)or oligoglycosylceramide with one or more sialic acids (i.e. n-acetylneuraminic acid) linked on the sugar chain. It is a component the cell plasma membrane which modulates cell signal transduction events. Gangliosides have been found to be highly important in immunology. Ganglioside GM3 carries a net-negative charge at pH 7.0 and is acidic. Gangliosides can amount to 6% of the weight of lipids from brain, but they are found at low levels in all animal tissuesGangliosides are glycosphingolipids. There are four types of glycosphingolipids, the cerebrosides, sulfatides, globosides and gangliosides. Gangliosides are very similar to globosides except that they also contain N-acetyl neuraminic acid (NANA) in varying amounts. The specific names for the gangliosides provide information about their structure. The letter G refers to ganglioside, and the subscripts M, D, T and Q indicate that the molecule contains mono-, di-, tri and quatra-sialic acid. The numbered subscripts 1, 2 and 3 refer to the carbohydrate sequence that is attached to the ceramide. In particular, 1 stands for GalGalNAcGalGlc-ceramide, 2 stands for GalNAcGalGlc-ceramide and 3 stands for GalGlc-ceramide. Deficiencies in lysosomal enzymes that degrade the carbohydrate portions of various gangliosides are responsible for a number of lysosomal storage diseases such as Tay-Sachs disease, Sandhoff disease, and GM1 gangliosidosis. The carbohydrate portion of the ganglioside GM1 is the site of attachment of cholera toxin, the protein secreted by Vibrio cholerae.[HMDB0004844] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000090|GTC:G91237TK|CID:[https://pubmed.ncbi.nlm.nih.gov/5288424 5288424]|CHEBI:59226|GlycoEpitope:EP0053|SugarBind_Ligand:35 <br> | '''term_xref''' : GlycoMotif:GGM.000090|GTC:G91237TK|CID:[https://pubmed.ncbi.nlm.nih.gov/5288424 5288424]|CHEBI:59226|GlycoEpitope:EP0053|SugarBind_Ligand:35 <br> | ||
| Line 116: | Line 116: | ||
'''glycan_dictionary_accession''' : GSD000094 <br> | '''glycan_dictionary_accession''' : GSD000094 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G30207PZ G30207PZ] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G30207PZ G30207PZ] <br> | ||
'''term_in_sentence''' : GM4 is synthesized by the sialylation of galactosylceramide (GalCer), while the ganglioside GM3 is synthesized by the sialylation of lactosylceramide (LacCer).[PMID:[https://pubmed.ncbi.nlm.nih.gov/ | '''term_in_sentence''' : GM4 is synthesized by the sialylation of galactosylceramide (GalCer), while the ganglioside GM3 is synthesized by the sialylation of lactosylceramide (LacCer).[PMID:[https://pubmed.ncbi.nlm.nih.gov/23999868 23999868]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/ | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/23999868 23999868]|[https://pubmed.ncbi.nlm.nih.gov/2332419 2332419]|[https://pubmed.ncbi.nlm.nih.gov/12091485 12091485]|[https://pubmed.ncbi.nlm.nih.gov/19542236 19542236]|[https://pubmed.ncbi.nlm.nih.gov/8407875 8407875]|[https://pubmed.ncbi.nlm.nih.gov/23320941 23320941]|[https://pubmed.ncbi.nlm.nih.gov/28808804 28808804]|[https://pubmed.ncbi.nlm.nih.gov/3621237 3621237]|[https://pubmed.ncbi.nlm.nih.gov/23203271 23203271]|[https://pubmed.ncbi.nlm.nih.gov/7057115 7057115]|[https://pubmed.ncbi.nlm.nih.gov/26362868 26362868]|[https://pubmed.ncbi.nlm.nih.gov/6170387 6170387]|[https://pubmed.ncbi.nlm.nih.gov/18034482 18034482]|[https://pubmed.ncbi.nlm.nih.gov/7076644 7076644]|[https://pubmed.ncbi.nlm.nih.gov/2391348 2391348]|[https://pubmed.ncbi.nlm.nih.gov/25464080 25464080]|[https://pubmed.ncbi.nlm.nih.gov/3701369 3701369]|[https://pubmed.ncbi.nlm.nih.gov/11217952 11217952]|[https://pubmed.ncbi.nlm.nih.gov/6201236 6201236]|[https://pubmed.ncbi.nlm.nih.gov/30744426 30744426]|[https://pubmed.ncbi.nlm.nih.gov/9388026 9388026]|[https://pubmed.ncbi.nlm.nih.gov/27177620 27177620]|[https://pubmed.ncbi.nlm.nih.gov/30246056 30246056]|[https://pubmed.ncbi.nlm.nih.gov/15979459 15979459]|[https://pubmed.ncbi.nlm.nih.gov/7586078 7586078]|[https://pubmed.ncbi.nlm.nih.gov/6779816 6779816]|[https://pubmed.ncbi.nlm.nih.gov/29402905 29402905]|[https://pubmed.ncbi.nlm.nih.gov/7335153 7335153]|[https://pubmed.ncbi.nlm.nih.gov/3306476 3306476]|[https://pubmed.ncbi.nlm.nih.gov/17499534 17499534]|[https://pubmed.ncbi.nlm.nih.gov/7074082 7074082]|[https://pubmed.ncbi.nlm.nih.gov/9668345 9668345]|[https://pubmed.ncbi.nlm.nih.gov/3701884 3701884]|[https://pubmed.ncbi.nlm.nih.gov/26862430 26862430]|[https://pubmed.ncbi.nlm.nih.gov/6831238 6831238]|[https://pubmed.ncbi.nlm.nih.gov/27311552 27311552]|[https://pubmed.ncbi.nlm.nih.gov/26831445 26831445]|[https://pubmed.ncbi.nlm.nih.gov/24417799 24417799]|[https://pubmed.ncbi.nlm.nih.gov/7097284 7097284]|[https://pubmed.ncbi.nlm.nih.gov/4169231 4169231]|[https://pubmed.ncbi.nlm.nih.gov/16854400 16854400]|[https://pubmed.ncbi.nlm.nih.gov/26483798 26483798] <br> | ||
'''definition''' : An amino disaccharide consisting of β-D-galactose having an α-N-acetylneuraminyl residue attached at the 3-position | '''definition''' : An amino disaccharide consisting of β-D-galactose having an α-N-acetylneuraminyl residue attached at the 3-position | ||
[CHEBI:63155] <br> | [CHEBI:63155] <br> | ||
| Line 133: | Line 133: | ||
'''glycan_dictionary_accession''' : GSD000095 <br> | '''glycan_dictionary_accession''' : GSD000095 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G93805MV G93805MV] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G93805MV G93805MV] <br> | ||
'''term_in_sentence''' : n this report, we describe an efficient convergent synthesis of the GP1c glycolipid epitope, which is one of the most complex c-series gangliosides. [PMID:[https://pubmed.ncbi.nlm.nih.gov/ | '''term_in_sentence''' : n this report, we describe an efficient convergent synthesis of the GP1c glycolipid epitope, which is one of the most complex c-series gangliosides. [PMID:[https://pubmed.ncbi.nlm.nih.gov/19053458 19053458]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/1606358 1606358] [https://pubmed.ncbi.nlm.nih.gov/1606358 1606358]] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/1606358 1606358] [https://pubmed.ncbi.nlm.nih.gov/1606358 1606358]]]|[https://pubmed.ncbi.nlm.nih.gov/ | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/1606358 1606358] [https://pubmed.ncbi.nlm.nih.gov/1606358 1606358]] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/1606358 1606358] [https://pubmed.ncbi.nlm.nih.gov/1606358 1606358]]]|[https://pubmed.ncbi.nlm.nih.gov/19053458 19053458]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/1695858 1695858] [https://pubmed.ncbi.nlm.nih.gov/1695858 1695858]]|[https://pubmed.ncbi.nlm.nih.gov/4091974 4091974]|[https://pubmed.ncbi.nlm.nih.gov/10775425 10775425]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2468656 2468656] [https://pubmed.ncbi.nlm.nih.gov/2468656 2468656]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2299350 2299350] [https://pubmed.ncbi.nlm.nih.gov/2299350 2299350]]|[https://pubmed.ncbi.nlm.nih.gov/3064875 3064875]|[https://pubmed.ncbi.nlm.nih.gov/11432974 11432974]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9613831 9613831] [https://pubmed.ncbi.nlm.nih.gov/9613831 9613831]] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9613831 9613831] [https://pubmed.ncbi.nlm.nih.gov/9613831 9613831]]]|[https://pubmed.ncbi.nlm.nih.gov/11831845 11831845]|[https://pubmed.ncbi.nlm.nih.gov/1879553 1879553]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10699494 10699494] [https://pubmed.ncbi.nlm.nih.gov/10699494 10699494]] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10699494 10699494] [https://pubmed.ncbi.nlm.nih.gov/10699494 10699494]]]|[https://pubmed.ncbi.nlm.nih.gov/8969459 8969459]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/8474578 8474578] [https://pubmed.ncbi.nlm.nih.gov/8474578 8474578]] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/8474578 8474578] [https://pubmed.ncbi.nlm.nih.gov/8474578 8474578]]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/12031286 12031286] [https://pubmed.ncbi.nlm.nih.gov/12031286 12031286]]|[https://pubmed.ncbi.nlm.nih.gov/1304332 1304332]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9153001 9153001] [https://pubmed.ncbi.nlm.nih.gov/9153001 9153001]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10564776 10564776] [https://pubmed.ncbi.nlm.nih.gov/10564776 10564776]] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10564776 10564776] [https://pubmed.ncbi.nlm.nih.gov/10564776 10564776]]] <br> | ||
'''definition''' : <br> | '''definition''' : <br> | ||
'''term_xref''' : GlycoMotif:GGM.000118|GTC:G93805MV <br> | '''term_xref''' : GlycoMotif:GGM.000118|GTC:G93805MV <br> | ||
| Line 149: | Line 149: | ||
'''glycan_dictionary_accession''' : GSD000096 <br> | '''glycan_dictionary_accession''' : GSD000096 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G18625KA G18625KA] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G18625KA G18625KA] <br> | ||
'''term_in_sentence''' : Bilateral infusion of GQ1b into the hippocampus ameliorates cognitive deficits in the triple-transgenic AD mouse model (3xTg-AD).[PMID:[https://pubmed.ncbi.nlm.nih.gov/ | '''term_in_sentence''' : Bilateral infusion of GQ1b into the hippocampus ameliorates cognitive deficits in the triple-transgenic AD mouse model (3xTg-AD).[PMID:[https://pubmed.ncbi.nlm.nih.gov/31186474 31186474]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/ | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30798387 30798387]|[https://pubmed.ncbi.nlm.nih.gov/31186474 31186474]|[https://pubmed.ncbi.nlm.nih.gov/26704905 26704905]|[https://pubmed.ncbi.nlm.nih.gov/23677659 23677659]|[https://pubmed.ncbi.nlm.nih.gov/26984947 26984947]|[https://pubmed.ncbi.nlm.nih.gov/24184316 24184316]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/23804237 23804237] [https://pubmed.ncbi.nlm.nih.gov/23804237 23804237]]|[https://pubmed.ncbi.nlm.nih.gov/9819299 9819299]|[https://pubmed.ncbi.nlm.nih.gov/18514410 18514410]|[https://pubmed.ncbi.nlm.nih.gov/22189683 22189683]|[https://pubmed.ncbi.nlm.nih.gov/24859332 24859332] <br> | ||
'''definition''' : An amino oligosaccharide that is a branched octasaccharide derivative consisting of four sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end.[CHEBI:59212] <br> | '''definition''' : An amino oligosaccharide that is a branched octasaccharide derivative consisting of four sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end.[CHEBI:59212] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000115|GTC:G18625KA|GlycoEpitope:EP0069|CID:[https://pubmed.ncbi.nlm.nih.gov/45266843 45266843]|KEGG:G00117|CHEBI:59212 <br> | '''term_xref''' : GlycoMotif:GGM.000115|GTC:G18625KA|GlycoEpitope:EP0069|CID:[https://pubmed.ncbi.nlm.nih.gov/45266843 45266843]|KEGG:G00117|CHEBI:59212 <br> | ||
| Line 165: | Line 165: | ||
'''glycan_dictionary_accession''' : GSD000097 <br> | '''glycan_dictionary_accession''' : GSD000097 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G54733XO G54733XO] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G54733XO G54733XO] <br> | ||
'''term_in_sentence''' : A few studies have reported the association of autoantibodies to GM1 or GQ1bα with Alzheimer's disease (AD) or vascular dementia.[PMID:[https://pubmed.ncbi.nlm.nih.gov/ | '''term_in_sentence''' : A few studies have reported the association of autoantibodies to GM1 or GQ1bα with Alzheimer's disease (AD) or vascular dementia.[PMID:[https://pubmed.ncbi.nlm.nih.gov/25024341 25024341]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/ | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/25024341 25024341]|[https://pubmed.ncbi.nlm.nih.gov/23717411 23717411]|[https://pubmed.ncbi.nlm.nih.gov/17870542 17870542]|[https://pubmed.ncbi.nlm.nih.gov/10702226 10702226]|[https://pubmed.ncbi.nlm.nih.gov/21137678 21137678]|[https://pubmed.ncbi.nlm.nih.gov/26748510 26748510]|[https://pubmed.ncbi.nlm.nih.gov/8662799 8662799]|[https://pubmed.ncbi.nlm.nih.gov/21274438 21274438]|[https://pubmed.ncbi.nlm.nih.gov/24649890 24649890]|[https://pubmed.ncbi.nlm.nih.gov/16580208 16580208]|[https://pubmed.ncbi.nlm.nih.gov/28124591 28124591]|[https://pubmed.ncbi.nlm.nih.gov/20095613 20095613]|[https://pubmed.ncbi.nlm.nih.gov/17507233 17507233]|[https://pubmed.ncbi.nlm.nih.gov/23565921 23565921]|[https://pubmed.ncbi.nlm.nih.gov/14505645 14505645]|[https://pubmed.ncbi.nlm.nih.gov/20930939 20930939]|[https://pubmed.ncbi.nlm.nih.gov/9201997 9201997] <br> | ||
'''definition''' : <br> | '''definition''' : <br> | ||
'''term_xref''' : GlycoMotif:GGM.000116|GTC:G54733XO <br> | '''term_xref''' : GlycoMotif:GGM.000116|GTC:G54733XO <br> | ||
| Line 181: | Line 181: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G99524KA G99524KA] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G99524KA G99524KA] <br> | ||
'''term_in_sentence''' : The neural specific monoclonal antibody A2B5 was found to interact with GQ1c but not with Gq1b, nor did it interact with other glycolipids such as GM1, GD1a, GD1b, GT1a, GT1b and GA1.[PMID: 6640289] <br> | '''term_in_sentence''' : The neural specific monoclonal antibody A2B5 was found to interact with GQ1c but not with Gq1b, nor did it interact with other glycolipids such as GM1, GD1a, GD1b, GT1a, GT1b and GA1.[PMID: 6640289] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/6640289 6640289]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/1695858 1695858] [https://pubmed.ncbi.nlm.nih.gov/1695858 1695858]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/7798936 7798936] [https://pubmed.ncbi.nlm.nih.gov/7798936 7798936]]|[https://pubmed.ncbi.nlm.nih.gov/1729139 1729139]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2468656 2468656] [https://pubmed.ncbi.nlm.nih.gov/2468656 2468656]]|[https://pubmed.ncbi.nlm.nih.gov/ | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/6640289 6640289]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/1695858 1695858] [https://pubmed.ncbi.nlm.nih.gov/1695858 1695858]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/7798936 7798936] [https://pubmed.ncbi.nlm.nih.gov/7798936 7798936]]|[https://pubmed.ncbi.nlm.nih.gov/1729139 1729139]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2468656 2468656] [https://pubmed.ncbi.nlm.nih.gov/2468656 2468656]]|[https://pubmed.ncbi.nlm.nih.gov/20368669 20368669]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/2723647 2723647] [https://pubmed.ncbi.nlm.nih.gov/2723647 2723647]]|[https://pubmed.ncbi.nlm.nih.gov/1814411 1814411]|[https://pubmed.ncbi.nlm.nih.gov/3064875 3064875]|[https://pubmed.ncbi.nlm.nih.gov/6085330 6085330]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/1613492 1613492] [https://pubmed.ncbi.nlm.nih.gov/1613492 1613492]]|[https://pubmed.ncbi.nlm.nih.gov/17883393 17883393]|[https://pubmed.ncbi.nlm.nih.gov/11831845 11831845]|[https://pubmed.ncbi.nlm.nih.gov/10775425 10775425]|[https://pubmed.ncbi.nlm.nih.gov/8219015 8219015]|[https://pubmed.ncbi.nlm.nih.gov/8804704 8804704]|[https://pubmed.ncbi.nlm.nih.gov/1384262 1384262]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/7066685 7066685] [https://pubmed.ncbi.nlm.nih.gov/7066685 7066685]]|[https://pubmed.ncbi.nlm.nih.gov/2299192 2299192]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9613831 9613831] [https://pubmed.ncbi.nlm.nih.gov/9613831 9613831]]|[https://pubmed.ncbi.nlm.nih.gov/10350354 10350354]|[https://pubmed.ncbi.nlm.nih.gov/1304337 1304337]|[https://pubmed.ncbi.nlm.nih.gov/9153001 9153001]|[https://pubmed.ncbi.nlm.nih.gov/11959025 11959025]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/8474578 8474578] [https://pubmed.ncbi.nlm.nih.gov/8474578 8474578]]|[https://pubmed.ncbi.nlm.nih.gov/2299350 2299350]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10564776 10564776] [https://pubmed.ncbi.nlm.nih.gov/10564776 10564776]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10699494 10699494] [https://pubmed.ncbi.nlm.nih.gov/10699494 10699494]]|[https://pubmed.ncbi.nlm.nih.gov/3942818 3942818]|[https://pubmed.ncbi.nlm.nih.gov/12031286 12031286]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/7361620 7361620] [https://pubmed.ncbi.nlm.nih.gov/7361620 7361620]] <br> | ||
'''definition''' : Alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)-[alpha-Neu5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->4)]-beta-D-Galp-(1->4)-beta-D-Glcp is a member of neuraminic acids and an amino octasaccharide.[CID:[https://pubmed.ncbi.nlm.nih.gov/ | '''definition''' : Alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)-[alpha-Neu5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->4)]-beta-D-Galp-(1->4)-beta-D-Glcp is a member of neuraminic acids and an amino octasaccharide.[CID:[https://pubmed.ncbi.nlm.nih.gov/91860352 91860352]] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000117|GTC:G99524KA|CID:[https://pubmed.ncbi.nlm.nih.gov/ | '''term_xref''' : GlycoMotif:GGM.000117|GTC:G99524KA|CID:[https://pubmed.ncbi.nlm.nih.gov/91860352 91860352]|CHEBI:145645|KEGG:G00121 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
| Line 196: | Line 196: | ||
'''glycan_dictionary_accession''' : GSD000099 <br> | '''glycan_dictionary_accession''' : GSD000099 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G68110IF G68110IF] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G68110IF G68110IF] <br> | ||
'''term_in_sentence''' : GT1a mimicry was found in the lipo-oligosaccharides of strain ICDCCJ07002 and ICDCCJ07004; but a combination of GM3/GD3 mimics was observed in ICDCCJ07001, although this patient had anti-GT1a IgG antibodies.[PMID:[https://pubmed.ncbi.nlm.nih.gov/ | '''term_in_sentence''' : GT1a mimicry was found in the lipo-oligosaccharides of strain ICDCCJ07002 and ICDCCJ07004; but a combination of GM3/GD3 mimics was observed in ICDCCJ07001, although this patient had anti-GT1a IgG antibodies.[PMID:[https://pubmed.ncbi.nlm.nih.gov/26197476 26197476]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12023422 12023422]|[https://pubmed.ncbi.nlm.nih.gov/32623212 32623212]|[https://pubmed.ncbi.nlm.nih.gov/ | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12023422 12023422]|[https://pubmed.ncbi.nlm.nih.gov/32623212 32623212]|[https://pubmed.ncbi.nlm.nih.gov/26197476 26197476]|[https://pubmed.ncbi.nlm.nih.gov/9585812 9585812]|[https://pubmed.ncbi.nlm.nih.gov/29747820 29747820]|[https://pubmed.ncbi.nlm.nih.gov/23804237 23804237]|[https://pubmed.ncbi.nlm.nih.gov/11993188 11993188]|[https://pubmed.ncbi.nlm.nih.gov/31683059 31683059]|[https://pubmed.ncbi.nlm.nih.gov/19631994 19631994]|[https://pubmed.ncbi.nlm.nih.gov/9742882 9742882]|[https://pubmed.ncbi.nlm.nih.gov/29709941 29709941]|[https://pubmed.ncbi.nlm.nih.gov/8971119 8971119]|[https://pubmed.ncbi.nlm.nih.gov/8706663 8706663]|893404|[https://pubmed.ncbi.nlm.nih.gov/31829433 31829433]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/8910600 8910600] [https://pubmed.ncbi.nlm.nih.gov/8910600 8910600]]|[https://pubmed.ncbi.nlm.nih.gov/30600291 30600291]|[https://pubmed.ncbi.nlm.nih.gov/29319803 29319803]|[https://pubmed.ncbi.nlm.nih.gov/26176883 26176883]|[https://pubmed.ncbi.nlm.nih.gov/29063860 29063860]|[https://pubmed.ncbi.nlm.nih.gov/6766128 6766128]|[https://pubmed.ncbi.nlm.nih.gov/31602715 31602715]|[https://pubmed.ncbi.nlm.nih.gov/29808463 29808463]|[https://pubmed.ncbi.nlm.nih.gov/30711390 30711390]|[https://pubmed.ncbi.nlm.nih.gov/29847988 29847988]|[https://pubmed.ncbi.nlm.nih.gov/30116054 30116054]|[https://pubmed.ncbi.nlm.nih.gov/28187751 28187751] <br> | ||
'''definition''' : A branched heptasaccharide derivative consisting of three sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end.[CHEBI:59215] <br> | '''definition''' : A branched heptasaccharide derivative consisting of three sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end.[CHEBI:59215] <br> | ||
'''term_xref''' : CID:[https://pubmed.ncbi.nlm.nih.gov/45266863 45266863]|GlycoMotif:GGM.000110|GTC:G68110IF|GlycoEpitope:EP0066|KEGG:G00112|CHEBI:59215 <br> | '''term_xref''' : CID:[https://pubmed.ncbi.nlm.nih.gov/45266863 45266863]|GlycoMotif:GGM.000110|GTC:G68110IF|GlycoEpitope:EP0066|KEGG:G00112|CHEBI:59215 <br> | ||
| Line 228: | Line 228: | ||
'''glycan_dictionary_accession''' : GSD000101 <br> | '''glycan_dictionary_accession''' : GSD000101 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G40183QN G40183QN] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G40183QN G40183QN] <br> | ||
'''term_in_sentence''' : GT1b ganglioside is axonally transported to the spinal cord dorsal horn and contributes to characteristics of neuropathic pain such as mechanical and thermal hypersensitivity.[PMID: [https://pubmed.ncbi.nlm.nih.gov/ | '''term_in_sentence''' : GT1b ganglioside is axonally transported to the spinal cord dorsal horn and contributes to characteristics of neuropathic pain such as mechanical and thermal hypersensitivity.[PMID: [https://pubmed.ncbi.nlm.nih.gov/32030804 32030804]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/ | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/32030804 32030804]|[https://pubmed.ncbi.nlm.nih.gov/26370787 26370787]|[https://pubmed.ncbi.nlm.nih.gov/32046393 32046393]|[https://pubmed.ncbi.nlm.nih.gov/9712688 9712688]|[https://pubmed.ncbi.nlm.nih.gov/7636307 7636307]|[https://pubmed.ncbi.nlm.nih.gov/9931455 9931455]|[https://pubmed.ncbi.nlm.nih.gov/25520869 25520869]|[https://pubmed.ncbi.nlm.nih.gov/19605473 19605473]|[https://pubmed.ncbi.nlm.nih.gov/17188834 17188834]|[https://pubmed.ncbi.nlm.nih.gov/10233751 10233751]|[https://pubmed.ncbi.nlm.nih.gov/22735313 22735313]|[https://pubmed.ncbi.nlm.nih.gov/20540782 20540782]|[https://pubmed.ncbi.nlm.nih.gov/22746533 22746533]|[https://pubmed.ncbi.nlm.nih.gov/1861141 1861141]|[https://pubmed.ncbi.nlm.nih.gov/19490186 19490186]|[https://pubmed.ncbi.nlm.nih.gov/9521848 9521848]|[https://pubmed.ncbi.nlm.nih.gov/11921200 11921200]|[https://pubmed.ncbi.nlm.nih.gov/10731661 10731661]|[https://pubmed.ncbi.nlm.nih.gov/31431523 31431523]|[https://pubmed.ncbi.nlm.nih.gov/15274627 15274627]|[https://pubmed.ncbi.nlm.nih.gov/32726962 32726962]|[https://pubmed.ncbi.nlm.nih.gov/12573517 12573517]|[https://pubmed.ncbi.nlm.nih.gov/18277613 18277613]|[https://pubmed.ncbi.nlm.nih.gov/11370834 11370834]|[https://pubmed.ncbi.nlm.nih.gov/11234774 11234774]|[https://pubmed.ncbi.nlm.nih.gov/11123278 11123278]|[https://pubmed.ncbi.nlm.nih.gov/18704164 18704164]|[https://pubmed.ncbi.nlm.nih.gov/16291967 16291967]|[https://pubmed.ncbi.nlm.nih.gov/11411041 11411041]|[https://pubmed.ncbi.nlm.nih.gov/27549393 27549393]|[https://pubmed.ncbi.nlm.nih.gov/25253868 25253868]|[https://pubmed.ncbi.nlm.nih.gov/22720883 22720883]|[https://pubmed.ncbi.nlm.nih.gov/10686582 10686582]|[https://pubmed.ncbi.nlm.nih.gov/11511306 11511306]|[https://pubmed.ncbi.nlm.nih.gov/29904724 29904724]|[https://pubmed.ncbi.nlm.nih.gov/31472390 31472390]|[https://pubmed.ncbi.nlm.nih.gov/19156870 19156870] <br> | ||
'''definition''' : A branched amino heptasaccharide comprising a β-D-galactosyl-(1→4)-β-D-glucose disaccharide, the galactosyl residue of which carries an N-acetyl-α-neuraminyl-(2→3)-β-D-galactosyl-(1→3)-N-acetyl-β-D-galactosaminyl trisaccharide unit and an N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl disaccharide unit through (2→4) and (2→3) linkages respectively. It corresponds to the carbohydrate portion of ganglioside GT1b.[CHEBI:59225] <br> | '''definition''' : A branched amino heptasaccharide comprising a β-D-galactosyl-(1→4)-β-D-glucose disaccharide, the galactosyl residue of which carries an N-acetyl-α-neuraminyl-(2→3)-β-D-galactosyl-(1→3)-N-acetyl-β-D-galactosaminyl trisaccharide unit and an N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl disaccharide unit through (2→4) and (2→3) linkages respectively. It corresponds to the carbohydrate portion of ganglioside GT1b.[CHEBI:59225] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000112|GTC:G40183QN|GlycoEpitopeEP0067|CID:[https://pubmed.ncbi.nlm.nih.gov/45266781 45266781]|CHEBI:59225| GlycoGlycoEpitope:130680|SugarBind_Ligand:26|KEGG:G00116<br> | '''term_xref''' : GlycoMotif:GGM.000112|GTC:G40183QN|GlycoEpitopeEP0067|CID:[https://pubmed.ncbi.nlm.nih.gov/45266781 45266781]|CHEBI:59225| GlycoGlycoEpitope:130680|SugarBind_Ligand:26|KEGG:G00116<br> | ||
| Line 244: | Line 244: | ||
'''glycan_dictionary_accession''' : GSD000102 <br> | '''glycan_dictionary_accession''' : GSD000102 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G78818SP G78818SP] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G78818SP G78818SP] <br> | ||
'''term_in_sentence''' : We show here that VVH associates with ganglioside GM1a, Fucosyl-GM1, GD1a, GT1c, and GD1b by glycan array.[PMID: [https://pubmed.ncbi.nlm.nih.gov/ | '''term_in_sentence''' : We show here that VVH associates with ganglioside GM1a, Fucosyl-GM1, GD1a, GT1c, and GD1b by glycan array.[PMID: [https://pubmed.ncbi.nlm.nih.gov/32228455 32228455]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28088450 28088450]|[https://pubmed.ncbi.nlm.nih.gov/30085356 30085356]|[https://pubmed.ncbi.nlm.nih.gov/ | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28088450 28088450]|[https://pubmed.ncbi.nlm.nih.gov/30085356 30085356]|[https://pubmed.ncbi.nlm.nih.gov/32228455 32228455]|[https://pubmed.ncbi.nlm.nih.gov/2468656 2468656]|[https://pubmed.ncbi.nlm.nih.gov/19841910 19841910]|[https://pubmed.ncbi.nlm.nih.gov/23877172 23877172]|[https://pubmed.ncbi.nlm.nih.gov/1695858 1695858]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10564776 10564776] [https://pubmed.ncbi.nlm.nih.gov/10564776 10564776]]|[https://pubmed.ncbi.nlm.nih.gov/1613492 1613492]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/8474578 8474578] [https://pubmed.ncbi.nlm.nih.gov/8474578 8474578]]|[https://pubmed.ncbi.nlm.nih.gov/7798936 7798936]|[https://pubmed.ncbi.nlm.nih.gov/11180643 11180643]|[https://pubmed.ncbi.nlm.nih.gov/2723647 2723647]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/7066685 7066685] [https://pubmed.ncbi.nlm.nih.gov/7066685 7066685]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9613831 9613831] [https://pubmed.ncbi.nlm.nih.gov/9613831 9613831]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/7361620 7361620] [https://pubmed.ncbi.nlm.nih.gov/7361620 7361620]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10699494 10699494] [https://pubmed.ncbi.nlm.nih.gov/10699494 10699494]] <br> | ||
'''definition''' : A branched amino heptasaccharide consisting of a linear tetrasaccharide of β-D-galactose, N-acetyl-β-D-galactosamine, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→4) and (1→4), to the galactose residue proximal to the reducing end is also linked (2→3) an N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl trisaccharide side-chain. The carbohydrate moiety of ganglioside GT1c.[CHEBI:90509] <br> | '''definition''' : A branched amino heptasaccharide consisting of a linear tetrasaccharide of β-D-galactose, N-acetyl-β-D-galactosamine, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→4) and (1→4), to the galactose residue proximal to the reducing end is also linked (2→3) an N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl trisaccharide side-chain. The carbohydrate moiety of ganglioside GT1c.[CHEBI:90509] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000113|GTC:G78818SP|CID:[https://pubmed.ncbi.nlm.nih.gov/91846734 91846734]|CHEBI:90509|GlycoEpitope:EP0033|KEGG:G00120 <br> | '''term_xref''' : GlycoMotif:GGM.000113|GTC:G78818SP|CID:[https://pubmed.ncbi.nlm.nih.gov/91846734 91846734]|CHEBI:90509|GlycoEpitope:EP0033|KEGG:G00120 <br> | ||
| Line 276: | Line 276: | ||
'''glycan_dictionary_accession''' : GSD000104 <br> | '''glycan_dictionary_accession''' : GSD000104 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G93899SO G93899SO] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G93899SO G93899SO] <br> | ||
'''term_in_sentence''' : The purpose of this study was two-fold: (1) to formulate γ-tocotrienol (GT3) in a nanoemulsion formulation as a prophylactic orally administered radioprotective agent; and (2) to optimize the storage conditions to preserve the structural integrity of both the formulation and the compound.[PMID: [https://pubmed.ncbi.nlm.nih.gov/ | '''term_in_sentence''' : The purpose of this study was two-fold: (1) to formulate γ-tocotrienol (GT3) in a nanoemulsion formulation as a prophylactic orally administered radioprotective agent; and (2) to optimize the storage conditions to preserve the structural integrity of both the formulation and the compound.[PMID: [https://pubmed.ncbi.nlm.nih.gov/28029115 28029115]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/ | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28029115 28029115]|[https://pubmed.ncbi.nlm.nih.gov/31355968 31355968]|[https://pubmed.ncbi.nlm.nih.gov/30987413 30987413]|[https://pubmed.ncbi.nlm.nih.gov/27869747 27869747]|[https://pubmed.ncbi.nlm.nih.gov/27216753 27216753]|[https://pubmed.ncbi.nlm.nih.gov/8631981 8631981]|[https://pubmed.ncbi.nlm.nih.gov/29672891 29672891]|[https://pubmed.ncbi.nlm.nih.gov/10385047 10385047]|[https://pubmed.ncbi.nlm.nih.gov/29642403 29642403]|[https://pubmed.ncbi.nlm.nih.gov/10412028 10412028]|[https://pubmed.ncbi.nlm.nih.gov/27193023 27193023]|[https://pubmed.ncbi.nlm.nih.gov/30068561 30068561]|[https://pubmed.ncbi.nlm.nih.gov/23415908 23415908]|[https://pubmed.ncbi.nlm.nih.gov/8858920 8858920]|[https://pubmed.ncbi.nlm.nih.gov/2303428 2303428]|[https://pubmed.ncbi.nlm.nih.gov/27153057 27153057]|[https://pubmed.ncbi.nlm.nih.gov/27128741 27128741]|[https://pubmed.ncbi.nlm.nih.gov/2654294 2654294]|[https://pubmed.ncbi.nlm.nih.gov/26930378 26930378]|[https://pubmed.ncbi.nlm.nih.gov/7561885 7561885]|[https://pubmed.ncbi.nlm.nih.gov/25860286 25860286]|[https://pubmed.ncbi.nlm.nih.gov/30845647 30845647]|[https://pubmed.ncbi.nlm.nih.gov/24712339 24712339]|[https://pubmed.ncbi.nlm.nih.gov/30070965 30070965]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/8910600 8910600] [https://pubmed.ncbi.nlm.nih.gov/8910600 8910600]]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/1606358 1606358] [https://pubmed.ncbi.nlm.nih.gov/1606358 1606358]]|[https://pubmed.ncbi.nlm.nih.gov/27356050 27356050]|[https://pubmed.ncbi.nlm.nih.gov/8514740 8514740]|[https://pubmed.ncbi.nlm.nih.gov/18509108 18509108]|[https://pubmed.ncbi.nlm.nih.gov/23000517 23000517]|[https://pubmed.ncbi.nlm.nih.gov/29769046 29769046]|[https://pubmed.ncbi.nlm.nih.gov/29566611 29566611] <br> | ||
'''definition''' : A linear amino pentasaccharide consisting of a chain of three α-sialyl residues, a β-D-galactosyl residue and a β-D-glucose residue linked sequentially (2→8), (2→8), (2→3) and (1→4).[CHEBI:72444] <br> | '''definition''' : A linear amino pentasaccharide consisting of a chain of three α-sialyl residues, a β-D-galactosyl residue and a β-D-glucose residue linked sequentially (2→8), (2→8), (2→3) and (1→4).[CHEBI:72444] <br> | ||
'''term_xref''' : GlycoEpitope:EP0070|KEGG:G00118|CID:[https://pubmed.ncbi.nlm.nih.gov/70788970 70788970]|GlycoMotif:GGM.000092|GTC:G93899SO|CHEBI:72444 <br> | '''term_xref''' : GlycoEpitope:EP0070|KEGG:G00118|CID:[https://pubmed.ncbi.nlm.nih.gov/70788970 70788970]|GlycoMotif:GGM.000092|GTC:G93899SO|CHEBI:72444 <br> | ||
Revision as of 17:59, 7 April 2023
Globoside
term (main_entry) : Globoside
glycan_dictionary_accession : GSD000087
glytoucan_accession : G00061MO
term_in_sentence : Results of TLC immunostaining of neutral glycolipids from the cDNA-transfected cells also supported the identity of the newly synthesized component as globoside. [PMID:[https://pubmed.ncbi.nlm.nih.gov/10993897 10993897 10993897]]
publication : 10993897
definition :
term_xref : GlycoMotif:GGM.000070|GTC:G00061MO
synonyms : Cytolipin K|Gb4|Globoside I|Globotetraosylceramide|P antigen
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 47
Globotetraosylceramide
term (main_entry) : Globotetraosylceramide
glycan_dictionary_accession : GSD000088
glytoucan_accession : G00061MO
term_in_sentence : Here we report that PUGNAc treatment provokes globotetraosylceramide (Gb4Cer) accumulation in human umbilical vein endothelial cells (HUVEC).[PMID:[https://pubmed.ncbi.nlm.nih.gov/28392398 28392398 28392398]]
publication : 28392398|25787850|23471986|2559078|32455599|2663859|32796033|3517161|20082214|30853699|15279935|26104834|20732996|30224239|31142708|30338271|25033755|[https://pubmed.ncbi.nlm.nih.gov/30413389 30413389 30413389]|7104376|29866658|24983355|6794884|31361021|21740983|33168837|31752441|28123520|29068380|24841197|27932383|28535204|31691795|27916888|27558838|10227680|26464281|22348006|22279060|25156739|32314902|22718629|23701631|23906628|8613382|23555772|20059899|7868240
definition : An amino tetrasaccharide consisting of 2-acetamido-2-deoxy-β-D-galactopyranosyl, α-D-galactopyranosyl, β-D-galactopyranosyl, and β-D-glucopyranose units joined together in sequence by (1→3), (1→4), and (1→4) glycosidic linkages, respectively.[CHEBI:145578]
term_xref : GlycoMotif:GGM.000070|GlycoEpitope:EP0073|CID:5288889|CHEBI:145578|SugarBind_Ligand:18|MeSH:C024032
synonyms : Gb4Cer|Gb4|Globoside|P antigen|Cytolipin K
function :
disease_associations : Actinomycosis[SugarBind_Ligand:18]|Pyelonephritis[SugarBind_Ligand:18]|Acute cystitis[SugarBind_Ligand:18]|Shigellosis[SugarBind_Ligand:18]|Lazy leukocyte syndrome[SugarBind_Ligand:18]|Influenza[SugarBind_Ligand:18]
wikipedia :
essentials_of_glycobiology : Chapter 11
Globotriaosylceramide
term (main_entry) : Globotriaosylceramide
glycan_dictionary_accession : GSD000089
glytoucan_accession : G00059MO
term_in_sentence : Defects in the gene encoding α-galactosidase A lead to accumulation of globotriaosylceramide (GL3) in various cell types.[PMID:32127409]
publication : 32127409|28674962|30875019|[https://pubmed.ncbi.nlm.nih.gov/30413389 30413389 30413389]|31778662|31101366|24335674|31241709|24158513|28947349|31566927|28672034|31939530|29530250|27851774|26426881|25031264|29982630|24496231|29983334|28756410|27190352|29274327|29099167|28402705|23680766|28625968|26960552|26797827|22742555|27756537|31630715|3827883|28384397|29523338|31010832|27195818|26661087|23093409|30879639|27081853|17409683|29921669|25575293|26291612|23146289|25857295|26070511
definition : Globotriaosylceramide is a type of globoside(glycosphingolipid) which is formed by alpha linkage of galactose to lactosylceramide. The reaction is catalyzed by enzyme A4GALT.[Wiki:Globotriaosylceramide]
term_xref : GlycoMotif:GGM.000068|GTC:G00059MO|GlycoEpitope:EP0071|CID:5279515|CHEBI:68485|MeSH:C018549|SugarBind_Ligand:27
synonyms : Gb3|GL3|Pk antigen|P^K antigen|Gb(3)|Gb_3|CD77|globotriaosylceramide|ceramide trihexoside|CTH|Trihexosylceramide
function :
disease_associations : Pyelonephritis[SugarBind_Ligand:27]|Acute cystitis[SugarBind_Ligand:27]|Shigellosis[SugarBind_Ligand:27]|Lyme disease[SugarBind_Ligand:27]|Cutaneous lesions[SugarBind_Ligand:27]|Diarrhea[SugarBind_Ligand:27]
wikipedia :
essentials_of_glycobiology :
Glucosylceramide
term (main_entry) : Glucosylceramide
glycan_dictionary_accession : GSD000090
glytoucan_accession : G71142DF
term_in_sentence : Glucosylceramide (GlcCer), the initial GSL synthesized from ceramide by GCS (GlcCer synthase), is required for embryonic survival, but its role in the lung is unknown.[PMID:31265321]
publication : 31265321|29290548|29627573|20919653|28427052|30550553|24415933|31914593|31051284|23073611|30146946|31619618|26840726|29750412|8065509|27412675|27840079|30611744|31353719|25661072|28686011|25803043|28865794|28154347|31466334|30242129|12531551|30639288|30864417|27711049|22764777|27905603|29077010|28744000|23555901|24115322|12803919|29204666|23628459|28851512|26136173|23563543|30110701|26572681|2193825|29926415|31727994|27479571
definition : Cerebrosides which contain as their polar head group a glucose moiety bound in glycosidic linkage to the hydroxyl group of ceramides. Their accumulation in tissue, due to a defect in beta-glucosidase, is the cause of Gaucher's disease.[MeSH:D005963]
term_xref : MeSH:D005963|GlycoMotif:GGM.000060|CHEBI:83264|GTC:G71142DF
synonyms : GlcCer|Glucocerebroside|Ceramide monohexoside|CMH
function : The structural characterization of mixed membranes made of cationic lipids and glucosylceramides may be important for developing novel immunotherapeutic tools such as vaccine adjuvants.[PMID:30611744]|Glucosylceramide (GlcCer), the initial GSL synthesized from ceramide by GCS (GlcCer synthase), is required for embryonic survival, but its role in the lung is unknown.[PMID:31265321]
disease_associations : Gaucher's Disease|Pharyngitis[SugarBind_Ligand:3]|Tracheobronchitis[SugarBind_Ligand:3]|Pleuropneumonia[SugarBind_Ligand:3]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:3]|Diarrhea[SugarBind_Ligand:3]
wikipedia :
essentials_of_glycobiology : Chapter 31
GM1
term (main_entry) : GM1
glycan_dictionary_accession : GSD000091
glytoucan_accession : G48558GR
term_in_sentence : GM1-induced fluidization of the phospholipid membranes and probable physical contact between bulky sugar head group of GM1 and spectrin, may explain the modulatory role of GM1 on aminophospholipid interactions with nonerythroid brain spectrin.[PMID: 29920238]
publication : 18524657|31761138|36180805|29920238|33859490|31937438|25762012|25931034|31776384|32013258|30776097|31048748|31447771|30292198|28796418|27806275|21076871|27552916|17986147|26960162|27815022|25851126|32916822|11462671|28236574|15911874|28577204|28497346|1794005|31934908|30267299|16902585|29439846|32325905|29747823|27576485|26338710|27858734|24501414|26818965|26629687|26958633|1854596|32134593|32198666|6619101
definition : A branched amino pentasaccharide consisting of the linear sequence β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the inner galactose via an α-(2→3) linkage. The oligosaccharide of ganglioside GM1a.[CHEBI:59208]
term_xref : GlycoMotif:GGM.000098|GTC:G48558GR|CID:196569|CHEBI:59208|GlycoEpitope:EP0050|SugarBind_Ligand:13|KEGG:G00110
synonyms : GM1 ganglioside|GM1-ganglioside
function : The branched pentasaccharide chain of ganglioside GM1 is a prominent cell surface ligand, for example, for cholera toxin or tumor growth-regulatory homodimeric galectins.[PMID:16267866]
disease_associations : GM1 gangliosidosis (GM1) [PMID: 33859490]|Gastroenteritis[SugarBind_Ligand:13]|Actinomycosis[SugarBind_Ligand:13]|Lazy leukocyte syndrome[SugarBind_Ligand:13]|Toxoplasmosis[SugarBind_Ligand:13]|Cholera[SugarBind_Ligand:13]|Botulism[SugarBind_Ligand:13]
wikipedia : https://en.wikipedia.org/wiki/GM1
essentials_of_glycobiology : Chapter 11| Chapter 14
GM2
term (main_entry) : GM2
glycan_dictionary_accession : GSD000092
glytoucan_accession : G79389NT
term_in_sentence : GM1 gangliosidosis has both central nervous system and systemic findings; while, GM2 gangliosidosis is restricted primarily to the central nervous system.[PMID: 27491214]
publication : 29618308|27491214|32867370|30030044|27499644|31097363|29100724|27402091|31852956|30389374|30988135|8786814|14533808|23370522|28192816|32692591|29106755|28833537|11339652|9728335|27270764|9714704|26175473|27018595|28615102|28974375|32951593|11462672|28955902|17192692|26538065|25421609|9572057|11596983|15264019|23236285|11596984|31261761|30113798|24391178|24309906|22224667|7980537|18272501|9006924|
definition : A branched amino tetrasaccharide consisting of the linear sequence β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the galactose via an α-(2→3) linkage. Corresponds to the carbohydrate portion of ganglioside GM2.[CHEBI:59220]
term_xref : GlycoMotif:GGM.000095|GTC:G79389NT|CID:45266845|CHEBI:59220|GlycoEpitope:EP0051|SugarBind_Ligand:39|KEGG:G00109|KEGG:G10351
synonyms :
function :
disease_associations : lung adenocarcinoma[GlycoEpitope:EP0051]|embryonal carcinoma[GlycoEpitope:EP0051]|germ cell tumor[GlycoEpitope:EP0051]|teratocarcinoma[GlycoEpitope:EP0051]|squamous cell carcinoma[GlycoEpitope:EP0051]|Gastroenteritis[SugarBind_Ligand:39]|Cholera[SugarBind_Ligand:39]|Clostridial myonecrosis[SugarBind_Ligand:39]|Tetanus[SugarBind_Ligand:39]
wikipedia : https://en.wikipedia.org/wiki/GM1_gangliosidoses
essentials_of_glycobiology : Chapter 11
GM3
term (main_entry) : GM3
glycan_dictionary_accession : GSD000093
glytoucan_accession : G91237TK
term_in_sentence : We also demonstrated an essential role of GM3 in murine and human auditory systems; a common pathological feature of GM3S deficiency is deafness. [PMID: 29747813]
publication : 29376491|29747813|25613425|30318083|31526872|31004109|28019668|26434718|27313500|27539856|30111401|28544772|29407985|19364317|30190430|31297734|30091781|26043887|32183071|30665141|27873002|25801320|30209782|32378734|23050851|22768242|14993837|24934090|17638075|21518140|26102277|19759399|24502144|25303960|23564406|16636105|16491123|11259118|15102521|12724312|24985965|8496625|25403557|15690123|15939439|25893133|23591593|20634908|2004380|739008|
definition : Ganglioside GM3 (d18:1/16:0) is a glycosphingolipid (ceramide and oligosaccharide)or oligoglycosylceramide with one or more sialic acids (i.e. n-acetylneuraminic acid) linked on the sugar chain. It is a component the cell plasma membrane which modulates cell signal transduction events. Gangliosides have been found to be highly important in immunology. Ganglioside GM3 carries a net-negative charge at pH 7.0 and is acidic. Gangliosides can amount to 6% of the weight of lipids from brain, but they are found at low levels in all animal tissuesGangliosides are glycosphingolipids. There are four types of glycosphingolipids, the cerebrosides, sulfatides, globosides and gangliosides. Gangliosides are very similar to globosides except that they also contain N-acetyl neuraminic acid (NANA) in varying amounts. The specific names for the gangliosides provide information about their structure. The letter G refers to ganglioside, and the subscripts M, D, T and Q indicate that the molecule contains mono-, di-, tri and quatra-sialic acid. The numbered subscripts 1, 2 and 3 refer to the carbohydrate sequence that is attached to the ceramide. In particular, 1 stands for GalGalNAcGalGlc-ceramide, 2 stands for GalNAcGalGlc-ceramide and 3 stands for GalGlc-ceramide. Deficiencies in lysosomal enzymes that degrade the carbohydrate portions of various gangliosides are responsible for a number of lysosomal storage diseases such as Tay-Sachs disease, Sandhoff disease, and GM1 gangliosidosis. The carbohydrate portion of the ganglioside GM1 is the site of attachment of cholera toxin, the protein secreted by Vibrio cholerae.[HMDB0004844]
term_xref : GlycoMotif:GGM.000090|GTC:G91237TK|CID:5288424|CHEBI:59226|GlycoEpitope:EP0053|SugarBind_Ligand:35
synonyms :
function : Membrane stabilizer|Energy source|Energy storage|Molecular messenger:|Signaling molecule[HMDB0004844]
disease_associations : Gastroenteritis[SugarBind_Ligand:35]|Chronic gastritis[SugarBind_Ligand:35]|Toxoplasmosis[SugarBind_Ligand:35]|Peptic ulcerSugarBind_Ligand:35]|Gastric cancer[SugarBind_Ligand:35]|Influenza[SugarBind_Ligand:35]|Diarrhea[SugarBind_Ligand:35]|Botulism[SugarBind_Ligand:35]
wikipedia :
essentials_of_glycobiology : Chapter 37
GM4
term (main_entry) : GM4
glycan_dictionary_accession : GSD000094
glytoucan_accession : G30207PZ
term_in_sentence : GM4 is synthesized by the sialylation of galactosylceramide (GalCer), while the ganglioside GM3 is synthesized by the sialylation of lactosylceramide (LacCer).[PMID:23999868]
publication : 23999868|2332419|12091485|19542236|8407875|23320941|28808804|3621237|23203271|7057115|26362868|6170387|18034482|7076644|2391348|25464080|3701369|11217952|6201236|30744426|9388026|27177620|30246056|15979459|7586078|6779816|29402905|7335153|3306476|17499534|7074082|9668345|3701884|26862430|6831238|27311552|26831445|24417799|7097284|4169231|16854400|26483798
definition : An amino disaccharide consisting of β-D-galactose having an α-N-acetylneuraminyl residue attached at the 3-position [CHEBI:63155]
term_xref : GlycoMotif:GGM.000089|GTC:G30207PZ|CID:5289366|CHEBI:63155|KEGG:G00317|SugarBind_Ligand:110
synonyms : Sialylated GalCer
function :
disease_associations : Chronic gastritis[SugarBind_Ligand:110]|Peptic ulcers[SugarBind_Ligand:110]|Gastric cancer[SugarBind_Ligand:110]
wikipedia :
essentials_of_glycobiology : Chapter 11|Chapter 15|Chapter 44|Appendix 45A
GP1c
term (main_entry) : GP1c
glycan_dictionary_accession : GSD000095
glytoucan_accession : G93805MV
term_in_sentence : n this report, we describe an efficient convergent synthesis of the GP1c glycolipid epitope, which is one of the most complex c-series gangliosides. [PMID:19053458]
publication : [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/1606358 1606358 1606358] [https://pubmed.ncbi.nlm.nih.gov/1606358 1606358 1606358]]|19053458|[https://pubmed.ncbi.nlm.nih.gov/1695858 1695858 1695858]|4091974|10775425|[https://pubmed.ncbi.nlm.nih.gov/2468656 2468656 2468656]|[https://pubmed.ncbi.nlm.nih.gov/2299350 2299350 2299350]|3064875|11432974|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/9613831 9613831 9613831] [https://pubmed.ncbi.nlm.nih.gov/9613831 9613831 9613831]]|11831845|1879553|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10699494 10699494 10699494] [https://pubmed.ncbi.nlm.nih.gov/10699494 10699494 10699494]]|8969459|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/8474578 8474578 8474578] [https://pubmed.ncbi.nlm.nih.gov/8474578 8474578 8474578]]|[https://pubmed.ncbi.nlm.nih.gov/12031286 12031286 12031286]|1304332|[https://pubmed.ncbi.nlm.nih.gov/9153001 9153001 9153001]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10564776 10564776 10564776] [https://pubmed.ncbi.nlm.nih.gov/10564776 10564776 10564776]]
definition :
term_xref : GlycoMotif:GGM.000118|GTC:G93805MV
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 11|Chapter 14|Chapter 27|Chapter 35|Chapter 45 |Chapter 47|Chapter 49
GQ1b
term (main_entry) : GQ1b
glycan_dictionary_accession : GSD000096
glytoucan_accession : G18625KA
term_in_sentence : Bilateral infusion of GQ1b into the hippocampus ameliorates cognitive deficits in the triple-transgenic AD mouse model (3xTg-AD).[PMID:31186474]
publication : 30798387|31186474|26704905|23677659|26984947|24184316|[https://pubmed.ncbi.nlm.nih.gov/23804237 23804237 23804237]|9819299|18514410|22189683|24859332
definition : An amino oligosaccharide that is a branched octasaccharide derivative consisting of four sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end.[CHEBI:59212]
term_xref : GlycoMotif:GGM.000115|GTC:G18625KA|GlycoEpitope:EP0069|CID:45266843|KEGG:G00117|CHEBI:59212
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 11
GQ1ba
term (main_entry) : GQ1ba
glycan_dictionary_accession : GSD000097
glytoucan_accession : G54733XO
term_in_sentence : A few studies have reported the association of autoantibodies to GM1 or GQ1bα with Alzheimer's disease (AD) or vascular dementia.[PMID:25024341]
publication : 25024341|23717411|17870542|10702226|21137678|26748510|8662799|21274438|24649890|16580208|28124591|20095613|17507233|23565921|14505645|20930939|9201997
definition :
term_xref : GlycoMotif:GGM.000116|GTC:G54733XO
synonyms : GQ1balpha
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GQ1c
term (main_entry) : GQ1c
glycan_dictionary_accession : GSD000098
glytoucan_accession : G99524KA
term_in_sentence : The neural specific monoclonal antibody A2B5 was found to interact with GQ1c but not with Gq1b, nor did it interact with other glycolipids such as GM1, GD1a, GD1b, GT1a, GT1b and GA1.[PMID: 6640289]
publication : 6640289|[https://pubmed.ncbi.nlm.nih.gov/1695858 1695858 1695858]|[https://pubmed.ncbi.nlm.nih.gov/7798936 7798936 7798936]|1729139|[https://pubmed.ncbi.nlm.nih.gov/2468656 2468656 2468656]|20368669|[https://pubmed.ncbi.nlm.nih.gov/2723647 2723647 2723647]|1814411|3064875|6085330|[https://pubmed.ncbi.nlm.nih.gov/1613492 1613492 1613492]|17883393|11831845|10775425|8219015|8804704|1384262|[https://pubmed.ncbi.nlm.nih.gov/7066685 7066685 7066685]|2299192|[https://pubmed.ncbi.nlm.nih.gov/9613831 9613831 9613831]|10350354|1304337|9153001|11959025|[https://pubmed.ncbi.nlm.nih.gov/8474578 8474578 8474578]|2299350|[https://pubmed.ncbi.nlm.nih.gov/10564776 10564776 10564776]|[https://pubmed.ncbi.nlm.nih.gov/10699494 10699494 10699494]|3942818|12031286|[https://pubmed.ncbi.nlm.nih.gov/7361620 7361620 7361620]
definition : Alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)-[alpha-Neu5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->4)]-beta-D-Galp-(1->4)-beta-D-Glcp is a member of neuraminic acids and an amino octasaccharide.[CID:91860352]
term_xref : GlycoMotif:GGM.000117|GTC:G99524KA|CID:91860352|CHEBI:145645|KEGG:G00121
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 46
GT1a
term (main_entry) : GT1a
glycan_dictionary_accession : GSD000099
glytoucan_accession : G68110IF
term_in_sentence : GT1a mimicry was found in the lipo-oligosaccharides of strain ICDCCJ07002 and ICDCCJ07004; but a combination of GM3/GD3 mimics was observed in ICDCCJ07001, although this patient had anti-GT1a IgG antibodies.[PMID:26197476]
publication : 12023422|32623212|26197476|9585812|29747820|23804237|11993188|31683059|19631994|9742882|29709941|8971119|8706663|893404|31829433|[https://pubmed.ncbi.nlm.nih.gov/8910600 8910600 8910600]|30600291|29319803|26176883|29063860|6766128|31602715|29808463|30711390|29847988|30116054|28187751
definition : A branched heptasaccharide derivative consisting of three sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end.[CHEBI:59215]
term_xref : CID:45266863|GlycoMotif:GGM.000110|GTC:G68110IF|GlycoEpitope:EP0066|KEGG:G00112|CHEBI:59215
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GT1a alpha
term (main_entry) : GT1a alpha
glycan_dictionary_accession : GSD000100
glytoucan_accession : G02149VR
term_in_sentence : A new class of gangliosides, GT1a alpha and GQ1b alpha, were initially identified as cholinergic neuron-specific antigens in bovine brain. [PMID:8082783]
publication : 7710562|8082783|10972137|9468624|9143254|8221098|9679279|11368158|11878808
definition :
term_xref : GlycoMotif:GGM.000111|GTC:G02149VR|GlycoEpitope:EP0111|CID:91851751|CHEBI:156678|KEGG:G00128
synonyms : GT1aa
function : GT1a alpha was a cholinerginic-specific antigen.[GlycoEpitope:EP0111]
disease_associations :
wikipedia :
essentials_of_glycobiology :
GT1b
term (main_entry) : GT1b
glycan_dictionary_accession : GSD000101
glytoucan_accession : G40183QN
term_in_sentence : GT1b ganglioside is axonally transported to the spinal cord dorsal horn and contributes to characteristics of neuropathic pain such as mechanical and thermal hypersensitivity.[PMID: 32030804]
publication : 32030804|26370787|32046393|9712688|7636307|9931455|25520869|19605473|17188834|10233751|22735313|20540782|22746533|1861141|19490186|9521848|11921200|10731661|31431523|15274627|32726962|12573517|18277613|11370834|11234774|11123278|18704164|16291967|11411041|27549393|25253868|22720883|10686582|11511306|29904724|31472390|19156870
definition : A branched amino heptasaccharide comprising a β-D-galactosyl-(1→4)-β-D-glucose disaccharide, the galactosyl residue of which carries an N-acetyl-α-neuraminyl-(2→3)-β-D-galactosyl-(1→3)-N-acetyl-β-D-galactosaminyl trisaccharide unit and an N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl disaccharide unit through (2→4) and (2→3) linkages respectively. It corresponds to the carbohydrate portion of ganglioside GT1b.[CHEBI:59225]
term_xref : GlycoMotif:GGM.000112|GTC:G40183QN|GlycoEpitopeEP0067|CID:45266781|CHEBI:59225| GlycoGlycoEpitope:130680|SugarBind_Ligand:26|KEGG:G00116
synonyms :
function :
disease_associations : Toxoplasmosis[SugarBind_Ligand:26]|Lyme disease[SugarBind_Ligand:26]|Cholera[SugarBind_Ligand:26]|Botulism[SugarBind_Ligand:26]|Tetanus[SugarBind_Ligand:26]|Influenza[SugarBind_Ligand:26]
wikipedia :
essentials_of_glycobiology :
GT1c
term (main_entry) : GT1c
glycan_dictionary_accession : GSD000102
glytoucan_accession : G78818SP
term_in_sentence : We show here that VVH associates with ganglioside GM1a, Fucosyl-GM1, GD1a, GT1c, and GD1b by glycan array.[PMID: 32228455]
publication : 28088450|30085356|32228455|2468656|19841910|23877172|1695858|[https://pubmed.ncbi.nlm.nih.gov/10564776 10564776 10564776]|1613492|[https://pubmed.ncbi.nlm.nih.gov/8474578 8474578 8474578]|7798936|11180643|2723647|[https://pubmed.ncbi.nlm.nih.gov/7066685 7066685 7066685]|[https://pubmed.ncbi.nlm.nih.gov/9613831 9613831 9613831]|[https://pubmed.ncbi.nlm.nih.gov/7361620 7361620 7361620]|[https://pubmed.ncbi.nlm.nih.gov/10699494 10699494 10699494]
definition : A branched amino heptasaccharide consisting of a linear tetrasaccharide of β-D-galactose, N-acetyl-β-D-galactosamine, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→4) and (1→4), to the galactose residue proximal to the reducing end is also linked (2→3) an N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl trisaccharide side-chain. The carbohydrate moiety of ganglioside GT1c.[CHEBI:90509]
term_xref : GlycoMotif:GGM.000113|GTC:G78818SP|CID:91846734|CHEBI:90509|GlycoEpitope:EP0033|KEGG:G00120
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GT2
term (main_entry) : GT2
glycan_dictionary_accession : GSD000103
glytoucan_accession : G36476BA
term_in_sentence : Biosynthesis of the c-series gangliosides GT3, GT2 and GP1c was studied in Golgi derived from rat liver.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1606358 1606358 1606358]]
publication : [https://pubmed.ncbi.nlm.nih.gov/1606358 1606358 1606358]|15498585|16005859|27540730|31533196|31201844
definition : A branched amino hexasaccharide consisting of a chain of three α-sialyl residues, a β-D-galactosyl residue and a β-D-glucose residue linked sequentially (2→8), (2→8), (2→3) and (1→4), to the galactosyl residue of which is also linked (1→4) an N-acetyl-β-D-galactosaminyl residue. The carbohydrate moiety of ganglioside GT2.[CHEBI:72446]
term_xref : GlycoMotif:GGM.000109|GTC:G36476BA|CID:70788971|CHEBI:72446|KEGG:G00119
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 11
GT3
term (main_entry) : GT3
glycan_dictionary_accession : GSD000104
glytoucan_accession : G93899SO
term_in_sentence : The purpose of this study was two-fold: (1) to formulate γ-tocotrienol (GT3) in a nanoemulsion formulation as a prophylactic orally administered radioprotective agent; and (2) to optimize the storage conditions to preserve the structural integrity of both the formulation and the compound.[PMID: 28029115]
publication : 28029115|31355968|30987413|27869747|27216753|8631981|29672891|10385047|29642403|10412028|27193023|30068561|23415908|8858920|2303428|27153057|27128741|2654294|26930378|7561885|25860286|30845647|24712339|30070965|[https://pubmed.ncbi.nlm.nih.gov/8910600 8910600 8910600]|[https://pubmed.ncbi.nlm.nih.gov/1606358 1606358 1606358]|27356050|8514740|18509108|23000517|29769046|29566611
definition : A linear amino pentasaccharide consisting of a chain of three α-sialyl residues, a β-D-galactosyl residue and a β-D-glucose residue linked sequentially (2→8), (2→8), (2→3) and (1→4).[CHEBI:72444]
term_xref : GlycoEpitope:EP0070|KEGG:G00118|CID:70788970|GlycoMotif:GGM.000092|GTC:G93899SO|CHEBI:72444
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 11